Author

Jacob Goodwin

Karolinska InstitutetORCID 0000-0002-3834-3071Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

Alireza AzimiiD· 1 shared Fan ZhangiD· 1 shared Fredrik Jerhammar· 1 shared Galina SelivanovaiD· 1 shared Ishani DasiD· 1 shared Jeroen MeliefiD· 1 shared Johan HanssoniD· 1 shared Klas G. WimaniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alireza AzimiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of BRAF/NRAS Status

Fan Zhang, Lola Boutin, Ishani Das, Jeroen Melief, Madhurendra Singh, Marina Stantic, Lu Zhang, Mohammad Alzrigat, Alireza Azimi, Lucas Baldran-Groves, Wesam Bazzar, Michelle S. Libério, Jacob Goodwin, Rainer Tuominen, Veronica Höiom, , Lars‐Gunnar Larsson

This study shows that combining palbociclib and crizotinib enhances senescence and immune recognition in melanoma cells regardless of BRAF/NRAS status, reducing tumor growth.

bioRxiv · Jul 4, 2025 · PreprintCancer Biology